



Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021

October 27, 2021 at 4:05 PM EDT

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).

Interested parties may access the conference call by dialing (844) 826-3033 (U.S.) or (412) 317-5185 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at <https://investors.exagen.com/>

A replay of the conference call will be available until Wednesday, November 17, 2021 at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 10161457. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE[®] brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen's goal is to enable providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For further information please visit www.exagen.com.

CONTACTS:

Investor Relations

Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525

Company

Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514



Source: Exagen Inc.